I think I shared your excitement, which is what lead me to share...

I think I shared your excitement, which is what lead me to share a lot of my early research here.. there just wasn't anyone talking about it and I know there are some very great posters on HC who would add greatly to the research over time. It all has to start somewhere, so at least we've got a discussion going now on HC, albeit still needing hard data before it garners a stronger following and contribution from other holders/posters.

For me, on paper CLTX CAR-T should be a game-changer when compared to current standard of care for GBM. If they have detected efficacy at the lowest dose, that is a major de-risk for me as I believe the only thing stopping this from partial and complete responses is the dosage. Safety is always going to be a major factor, so we'll need to be wary of any findings there.. but even with that, the FDA is likely going to tolerate side effects so long as it does not outweigh the benefit of the treatment (but so far, no safety concerns).

And if our CLTX trial is successful, it'll be the first of many follow up trials using CLTX as a 3rd gen, and/or paired with inhibitors or other combination therapies to increase the % of complete responses and partial responses. The value of CLTX right now is assuming none of this comes to fruition, but those who have done the research probably have a quiet confidence that the odds may just be in our favour. It makes a lot of sense on paper, it works in the lab.. now will that translate into the clinic? Just over a couple of weeks before we get a first glimpse of first in-human data!